

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 8-K

BIOMARIN PHARMACEUTICAL INC

Form 8-K

September 06, 2001

-----  
-----

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  
September 6, 2001 (September 6, 2001)

BioMarin Pharmaceutical Inc.  
(Exact name of registrant as specified in its charter)

Delaware  
(State or other jurisdiction  
of incorporation)

000-26727  
(Commission  
File Number)

68-0397820  
(IRS Employer Identification  
No.)

371 Bel Marin Keys Boulevard,  
Suite 210  
Novato, California  
(Address of principal  
executive offices)

94949  
(Zip Code)

(415) 884-6700  
(Registrant's telephone number, including area code)

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 8-K

-----  
-----  
  
Item 5. Other Events

On September 6, 2001, we announced the completion and the preliminary results of our Phase I clinical trial of recombinant human N-acetylgalactosamine 4-sulfatase (rhASB) for the treatment of MPS VI in a press release, dated September 6, 2001. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 7. Financial Statements and Exhibits

EXHIBIT NO.	DESCRIPTION OF DOCUMENT
99.1	Press Release Dated September 6, 2001 related to completion of MPS VI Phase I Trial.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BioMarin Pharmaceutical Inc.

By: /s/ Raymond W. Anderson

-----  
Raymond W. Anderson  
Chief Operating Officer, Chief Financial Officer,  
Secretary and Vice President Finance and  
Administration

Date: September 6, 2001

Exhibit Index

EXHIBIT NO.	DESCRIPTION OF DOCUMENT
99.1	Press Release Dated September 6, 2001 related to completion of MPS VI Phase I Trial.